HeartCare

Shanghai HeartCare Medical Technology Co., Ltd. (Stock Code: 06609.HK) was founded in 2016. The company is committed to improving the accessibility of innovative medical technologies and safeguarding life and health. Over six years, HeartCare has pioneered the creation of China's first one-stop solution for stroke treatment and prevention in the field of neurointervention. It boasts a full product pipeline ranging from the treatment of acute ischemic stroke and neurovascular stenosis, ischemic stroke prevention, hemorrhagic stroke treatment, to interventional access devices, with over 200 patent applications. Its sales channels cover all provinces in China except Hong Kong, Macao, and Taiwan. Building on its existing leading advantages, HeartCare will continue to focus on popularizing emerging medical procedures, addressing unmet clinical needs of doctors and patients in China. The company operates multiple emerging business segments including neurointervention, full cardiac treatment, pulmonary intervention, and computer-assisted technologies. HeartCare looks forward to continuously launching innovative interventional devices that define emerging procedures in these high-potential medical fields, reducing mortality rates of severe diseases and improving patient outcomes.